A breakthrough medical technology is nearing FDA review (and a $5B market)
Published on March 30, 2026.
TriAgenics' Zero3 TBA treatment aims to prevent the development of troublesome wisdom teeth from ever forming. The company's minimally invasive procedure can be performed by general dentists without surgery and could provide a new revenue stream for dental offices. The technology holds 37 patents and is currently being reviewed by the FDA. Early investors can earn up to 13% bonus stock in the company. However, early investment bonuses expire on February 3. The potential market for this technology is estimated at $5B annually.
Related Articles
Jacksonville research could be answer for high cholesterol through gene editing
Jacksonville is leading a pioneering gene editing study, aiming to treat severe cholesterol issues through the liver, with potential implications for long-term health.
NCCU students mourn classmate, call for stronger mental health support
North Carolina Central University students are mourning the death of sophomore Zyarre Prince, urging stronger support for mental health and bullying issues.
After MN focus, feds eye Medicaid fraud claims against other states
The Trump administration may withhold billions in federal health payments due to Medicaid fraud, mirroring Minnesota's actions, despite concerns about harm to vulnerable patients' services.